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ABSTRACT
Strongyloides stercoralis (S.S.) is a human intestinal parasite, which may lead to complicated strongy-
loidiasis. We report a case of disseminated strongyloidiasis following the treatment of myeloma. The 
patient developed skin lesions, respiratory distress, aseptic meningitis and bacterial and fungal sep-
sis. The diagnosis of strongyloidiasis was established through endotracheal tube secretions. Despite 
the treatment with Ivermectin and Albendazole, the outcome was fatal. The value of screening for 
strongyloidiasis is unclear but may be of benefi t in patients with hematological malignancies from 
high endemic areas.
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INTRODUCTION
Strongyloides stercoralis (S.S.) is a nematode 
that infects approximately 100 million hu-
mans worldwide each year. S.S. is endemic 
in tropical and subtropical regions, such as 
Africa, Southeast Asia, and Southeastern 
United States, and occurs sporadically in 
temperate areas.1,2
The life cycle of S.S. in humans begins 
when free-living infective filariform larvae 
penetrate the skin and migrate hematog-
enously to the lung,1,3,4 where they penetrate 
into the alveolar air sacs. The larvae then as-
cend the tracheobronchial tree and are swal-
lowed, thus accessing the duodenum and 
jejunum. The larvae develop into adult fe-
males, which lay eggs that hatch non-migra-
tory (rhabditiform) larvae that penetrate the 
mucosae, leading to internal autoinfection. 
This autoinfection cycle may persist and dis-
semination has been reported to occur in im-
munocompromised hosts.
The risk factors for hyper-infection and 
disseminated disease are immunosuppressive 
therapy (particularly steroids), human T-lym-
photropic virus 1 (HTLV1) infection, solid or-
gan transplantation, hematologic malignant 
disease, especially lymphoma and hypoglob-
ulinemia, hematopoietic bone marrow and 
stem cell transplantation, cancer chemother-
apy, chronic alcohol consumption, uremia, 
severe malnutrition and diabetes mellitus.1,3-8 
Of these, the most commonly reported risk 
factor is immunosupression due to steroids 
use. Out of more than 50 cases of hyper-
infection and disseminated infection have 
been reported since 2000, the use of ster-
oids was noted in 64% of cases.6 Steroids in-
duce hyper-infection due to suppression of 
eosinophilia3,9 and lymphocyte activation, 
and may also have a direct effect on the para-
sites themselves, accelerating the transfor-
mation of rhabditiform to invasive filariform 
larvae or rejuvenating reproductively latent 
adult females.1,3,6
Manifestations of infection can range 
from asymptomatic eosinophilia in the 
immunocompetent host to disseminated 
disease with septic shock in the immuno-
compromised host. Disseminated strongy-
loidiasis (D.S.) has been reported to occur 
in 1.5%-2.5% of all strongyloidiasis. In the 
absence of early diagnosis and treatment, the 
prognosis of (D.S.) is extremely poor.5
We present a case of a disseminated 
strongyloidiasis following the treatment of 
myeloma.
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CASE REPORT
The case was a 39-year-old Nepali man who had been resident 
in Qatar for the previous two years, not known to have any 
chronic disease. He was admitted to Hamad Medical Cor-
poration on June 2007 with fi ve days history of spinal cord 
compression symptoms. The investigation confi rmed the di-
agnosis of IgD Lambda multiple myeloma with extramedul-
lary localization, causing cord compression at different sites. 
The therapeutic plan was to treat him with the VAD proto-
col (Vincristine I.V. 0.4 mg/day for four days, Doxurobicine 
0.9 mg/kg/day for four days and Dexamethasone 40 mg/day 
for four days [day 1 to day 4, day 9 to day 12, day 17 to 
day 21]), four to six cycles monthly followed by autologous 
hematopoietic stem cell transplant, in addition to radio-
therapy for spinal cord compression. However, this protocol 
was delayed to avoid toxicity of concurrent chemoradiother-
apy, so he was started only on high dose of Dexamethasone 
40 mg/day for four days, three boluses (day 1 to day 4, day 9 
Figure 2: Wet mount from ETT.
Figure 1: Wet mount from sputum.
to day 12, day 17 to day 21), and radiotherapy, 30 grays frac-
tionated over 10 doses for two weeks on C3-D8. The patient 
also received 8 mg of Dexamethasone between boluses to 
prevent inﬂ ammatory reaction secondary to radiotherapy; 
he was also kept on supportive measures (Cotrimoxazole 
960 mg P.O. twice per week, Omeprazole 20 mg P.O. once 
daily, Zelodronic acid monthly and analgesics).
During the last session of radiotherapy he developed 
purpuric and serpiginous skin rash involving trunk, abdo-
men and upper thighs. Three days thereafter, he presented 
with bronchospasm, cough, hemoptysis, and dyspnea. The 
chest x-ray showed bilateral pulmonary infi ltrates suggest-
ing severe infection or pulmonary embolism. The patient 
was then transferred to the medical intensive care unit 
(MICU) for progressive respiratory deterioration, where he 
had been intubated for assisted ventilation. During his stay 
in the MICU, he continued to bleed from the endothracheal 
tube (ETT), developed fever, and was treated empirically 
with Tazocin and Ciproﬂ oxacin.
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Laboratory ﬁ ndings
The laboratory findings were WBC 9.6 x 109/L with 90% 
neutrophils and 10% lymphocytes, Hb 13.5 g/dL, plate-
let 150 x 109/L; Coagulation, liver function, and renal 
function were normal; Blood gas showed: pH 7.763, 
PCO
2
 32 mm Hg, Pa O
2
 63 mm Hg, HCO
3
 22 mmol/L; 
Blood culture, urine culture and stool culture were neg-
ative, the endotracheal tube secretions revealed larvae of 
S.S. (Figures 1, 2 and 3) The skin biopsy turned out to 
be vasculitis, daily endothracheal tube (ETT) samples in 
the following two weeks revealed the same result (larvae 
of S.S.). Stool examination was repeatedly negative for 
S.S. Strongyloidiasis serology was not available. The pa-
tient was started on Albendazole 400 mg daily through 
nasogastric tube for seven days and Ivermectin 200 mcg/
kg daily for two weeks.
Three weeks after his transfer to the MICU he had 
persistent fever, deterioration of the general conditions 
and developed skin herpetic lesions. Repeated ETT se-
cretions revealed Pseudomonas aeruginosa, Candida al-
bicans and hyphae filaments, but no larvae of S.S. Blood 
culture and stool cultures were negative, and urine 
culture showed Pseudomonas aeruginosa. Tazocin and 
Ciprofloxacin were switched to Meropenem and Vanco-
mycin. Two days later Caspofungin and Acyclovir were 
added. In spite of antibiotic, antiparasitic, antifungal 
and antiviral treatment, the patient continued to have 
persistent fever, respiratory failure and developed neu-
rological symptoms, like neck stiffness. Cerebrospinal 
fluid showed parameters suggestive of aseptic meningi-
tis (WBC 130/mm3 with neutrophil 24%, lymphocytes 
76%, protein 3.57 g/L, glucose 4 mmol/L and culture 
negative). Six weeks after his admission he died with 
septic shock.
DISCUSSION
Strongyloidiasis has caused Strongyloides stercoralis (S.S.) in-
fection. Manifestations of infection can range from asymp-
tomatic eosinophilia in the immunocompetent host to dis-
seminated disease in the immunocompromised host.3 The 
detection of increased number of larvae in the stool and/or 
sputum is a hallmark of hyper-infection.
In the case presented here, the patient was a citizen from Ne-
pal, an endemic area for S.S. He did not have a past history of gas-
trointestinal and respiratory disorders. There was no eosinophilia 
in his peripheral blood at the time the myeloma was diagnosed. 
Our patient had intrinsic immunological abnormalities due to 
multiple myeloma (hypoglobulinemia) and received high dose 
of steroids and radiotherapy. These factors may have allowed the 
development of disseminated strongyloidiasis. 
Clinically, hyper-infection syndrome or disseminated 
disease had seen reported to occur in up to 2.5% of all cases 
of strongyloidiasis infection.5 Most of the cases (70%) occur 
in men, with a median age of 51 years.6 The clinical mani-
festation vary: fever, chills may not always be present, but 
mal-absorption syndrome, paralytic ileus, ulcerative enteri-
tis and bleeding can complicate the disease.10
Pulmonary symptoms are among the most important signs 
of disseminated disease ranging from moderate to severe, in-
cluding cough, wheezing, dyspnea, chest pain, hemoptysis, and 
a chocking sensation. In the absence of early diagnosis and 
treatment, the patient develops severe pulmonary hemor-
rhage and respiratory failure. The chest x-ray most frequent-
ly shows bilateral focal interstitial infi ltrates.5,11 
Cutaneous symptoms are also frequent and include pru-
ritus, urticarial serpiginous rash called larvae currens, which 
is pathognomonic of S.S infection. These lesions are usually 
located in the lower trunk and thighs. Petechial and purpu-
ric rash of the same areas in which larvae have been demon-
strated in skin biopsy are reported. Skin manifestations of 
vasculitis, the underlying disease and/or associated Gram-
negative sepsis with disseminated intravascular coagulopa-
thy may also be present during hyper-infection.3 
Neurological manifestation can be seen: meningeal signs 
and symptoms is the most common indication of central nerv-
ous involvement.3,6 Usually, the spinal ﬂ uid show parameters 
of aseptic meningitis or demonstrates characteristics of Gram-
negative bacterial infection; larvae can be found in spinal ﬂ uid, 
meningeal vessels, dural, epidural, subdural and subrachnoid 
spaces. However, it has been reported that all organs could be 
involved if the diagnosis is not made until later.1,3,5,6
Hyper-infection is often complicated by bacterial and 
fungal infection,1,3,6,11 because of the leakage of gut ﬂ ora 
from a damaged bowel by moving larvae. Enteric bacteria 
are also carried by invasive larvae in their outer surfaces. 
This can result in septicemia, pneumonia, meningitis and 
disseminated bacterial or fungal infection in many parts 
of the body,1,11 massive secondary bacterial infections are 
Figure 3: Grain stain of sputum.
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frequently the immediate cause of death in patients with 
hyper-infection syndrome. 
The clinical course of the present case is typical of strongyloi-
diasis. Initially, the patient developed purpuric and serpiginous 
skin rash involving trunk, abdomen, and upper thighs, and pul-
monary symptoms including cough, bronchospasm, hemopty-
sis, and dyspnea. Previous infection with S.S. was not known and 
disseminated strongyloidiasis was not included in the differential 
diagnosis. Fortunately, identifi cation of strongyloidiasis larvae in 
the ETT secretions confi rmed the diagnosis. The patient also de-
veloped aseptic meningitis, bacterial and fungal pneumonia and 
urinary infection with Pseudomonas aeuruginosa.
The diagnosis in the immunocompromised (I.C) host is 
diffi cult because of a lower incidence of eosinophilia. The in-
fection may be diagnosed by multiple stool samples. In chronic 
strongyloidiasis, examination of more than three stool samples 
has a sensitivity of 60%-70%, and this may be higher in I.C. 
host.7,12 The separation and Bearman Concentration technique 
or stool culture may be used to improved detection of the larvae 
in stool. Infection may also be diagnosed by serology. A highly 
sensitive and specifi c Elisa serology has proven valuable in de-
tecting both symptomatic and asymptomatic S.S. infection.1,6,12 
Aspiration of duodenuo-jejunal ﬂ uid and small bowel biopsy 
or the use of strug test (Enterotest ®) may be required to detect 
S. larvae in such patients.10,12 Patients with pulmonary mani-
festations and suspected strongyloidiasis should have sputum 
culture and/or bronchoalveolar lavage5,11 for detection of S.S. in 
addition to ova, and parasites and Elisa testing. 
In our case, the diagnosis was made later. The larvae of 
S.S. were revealed by ETT and the stool analysis was nega-
tive; the skin biopsy showed only vasculitis and serology was 
not done. Gastrointestinal endoscopy with aspiration of du-
denuo-jejunal ﬂ uid and small bowel biopsy may have been 
required for earlier detection of SS. larvae, but the patient 
clinical condition did not allow further invasive procedures.
The goals of therapy for strongyloidiasis are to treat 
symptomatic disease and prevent complication in asympto-
matic disease by eradicating the organism to prevent autoin-
fection, which could cause hyper-infection.12 
For uncomplicated disease, current treatment options in-
clude Thiabendazole, Ivermectin and Albendazole. Thiaben-
dazole 25 mg/kg twice daily for three days, or Albendazole 
400 mg daily for seven days, or Ivermectin 200 mcg/kg in 
one or two doses in patients weighting more than 15 kg. The 
treatment is repeated if necessary 2-3 weeks after the fi rst 
course to ensure eradication of infection. Follow up stool 
examination should be performed over a period of three 
months after treatment to confi rm parasite eradication.6,13,14
For the hyper-infection syndrome, Ivermectin is recom-
mended to be administered daily until symptoms resolve, 
and stool test have been negative for at least two weeks.6 
Albendazole remains a potential alternative, but experience 
with its use is limited.4,14 
Mortality rate due to hyper-infection could be as high as 87%.1 
Most of the fatal infection caused by S.S. can be prevented by early 
detection and treatment of asymptomatic chronic infection.
Our patient was treated with Ivermectin 200 mcg/kg per day 
for two weeks and Albendazole 400 mg daily for one week, but 
the outcome was unfavorable, because of late diagnosis at the 
stage of disseminated disease, which was complicated by bacte-
rial and fungal infection.
The value of screening for strongyloidiasis is unclear, but may 
be of benefi t in patients from high endemic areas, essentially be-
fore the start of corticotherapy and chemotherapy.
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